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Introduction Hypogonadism is associated with 
poorer glycaemic outcomes/increased all-cause and 
cardiovascular morbidity/mortality in type 2 diabetes 
mellitus (T2DM). Increasing CAG repeat number within 
exon-1 of the androgen receptor (AR) gene is associated 
with increased AR resistance/insulin resistance.
Methods We determined in a long-term 14-year 
follow-up cohort of 423 T2DM Caucasian men, the 
association between baseline androgen status/CAG 
repeat number (by PCR then Sequenom sequencing) and 
metabolic/cardiovascular outcomes.
Results Metabolic outcomes: Lower total testosterone 
was associated with higher BMI (kg/m2) at 14-year-
follow-up: regression coefficient −0.30 (95% confidence 
interval −0.445 to −0.157), P = 0.0001. The range of 
CAG repeat number was 9-29 repeats. Higher CAG 
repeat number in exon-1 of the AR gene was associated 
with higher follow-up HbA1c2016 – each unit increase 
in CAG repeat-associated with an increment of 0.1% 
in HbA1C2016 (P = 0.04), independent of baseline 
testosterone. Cardiovascular outcomes and mortality: At 
an average of 14-year-follow-up, 55.8% of hypogonadal 
men had died vs 36.1% of eugonadal men (P = 0.001). 
There was a ‘u’ shaped relation between number of CAG 
repeats and mortality. Twenty-one CAG repeats were 
associated with an up to nearly 50% lower mortality 
rate than <21 CAG repeats and >21 CAG repeats – 
independent of baseline testosterone level.
Conclusion A higher number of CAG repeats at the 
AR gene associates with higher future HbA1c. There 
was a ‘u’ shaped relation between CAG repeat number 
and mortality rate. Determination of CAG repeat number 
may become part of assessment of androgen status/its 
consequences for men with T2DM. Cardiovasc Endocrinol 
Metab 10: 37–44 Copyright © 2020 Wolters Kluwer Health, 
Inc. All rights reserved.
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In men with type 2 diabetes mellitus, a higher number 
of CAG repeats at the androgen receptor gene is associ-
ated with a higher future HbA1c. We found a ‘u’ shaped 
relation between CAG repeat number and mortality rate, 
such that 21 CAG repeats was associated with an up to 
Learning points
(1) Hypogonadism has been associated with poorer 
glycaemic outcomes and increased cardiovascular 
morbidity/mortality in type 2 diabetes mellitus 
(T2DM).
(2) An increasing CAG repeat number within exon 1 of 
the androgen receptor gene polymorphism is associ-
ated with increased androgen receptor insensitivity.
(3) We here investigated the link between CAG 
repeat number and outcomes in T2DM men.
(4) There was a ‘u’ shaped relation between the num-
ber of CAG repeats and mortality such that 21 
CAG repeats was associated with an up to 58% 
lower mortality rate than <20 CAG repeats and 
>21 CAG repeats.
(5) CAG repeat number may become part of the 
assessment of androgen status for men in the future 
but further work in this area will be required.
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58% lower mortality rate than <20 CAG repeats and >21 
CAG repeats. independent of baseline testosterone level.
Introduction
Type 2 diabetes mellitus (T2DM) is a growing health 
issue around the world. In 2018, it was estimated that 
there were more than 500 million prevalent cases of 
T2DM worldwide with the prevalence comparable 
between high- and low-income countries [1]. Several 
studies have demonstrated a higher prevalence of hypo-
gonadism in T2DM men than those with normal glucose 
regulation and with type 1 diabetes (T1DM) [2–5]. In 
men with T2DM, low serum levels of total testosterone 
have been associated with a more adverse cardiometa-
bolic risk profile and with increased mortality [3,6–8], as 
also recently described in a long prospective UK cohort 
[9].
The androgen receptor (AR) mediates the peripheral 
effects of testosterone. The main mechanism of action for 
the AR is direct regulation of gene transcription. After the 
binding of an androgen to its receptor, a conformational 
change occurs, causing the dissociation of heat shock 
proteins, translocation into the nucleus, and dimeriza-
tion [10]. The AR dimer binds to a specific sequence of 
DNA, known as an androgen response element, thereby 
up- or downregulating specific gene transcription [6,11]. 
Testosterone effect occurs via the AR, through its more 
active metabolite, dihydrotestosterone (DHT) [10,12], in 
which it is converted by the enzyme 5-α reductase [3].
Testosterone may also act by a pathway that entails the 
rapid activation of kinase-signaling cascades and the mod-
ulation of intracellular calcium levels working directly on 
the calcium channel. This is a nongenomic effect [6,10].
The AR gene is composed of eight exons and is located 
on X chromosome at q11-q12. Exon 1 of the AR gene 
contains a polymorphic sequence of CAG repeats, 
which usually varies in number from 10 to 35, and which 
encodes polyglutamine stretches of the AR transactiva-
tion domain [6]. The evidence suggests that the CAG 
number is negatively correlated with the transcriptional 
activity of the AR [10,13].
Men affected by the Kennedy syndrome have more 
than 40 CAG repeats. The condition is characterized by 
decreased virilization, testicular atrophy, reduced sperm 
production, and infertility [14]. A shorter CAG repeat 
sequence has been associated with prostate disease, 
specifically cancer and benign hypertrophy, improved 
seminal parameters, and improved bone mineral density 
(BMD) [15,16]. Longer CAG repeat length in people 
with T2DM has been associated with greater waist cir-
cumference, serum leptin, and HDL cholesterol [6,13].
Our primary hypothesis was that the previously described 
relation between hypogonadism and fewer favorable 
outcomes in T2DM men is modulated by the number 
of CAG repeats at the AR gene with regard to long-term 
metabolic outcomes and mortality.
Aims
To measure initial testosterone, sex hormone binding 
globulin (SHBG), and testosterone receptor gene CAG 
repeat number and to ascertain the relation between ini-
tial androgen status and the number of the CAG repeats 
with (a) change in HbA1c/BMI over time (b) cardiovascu-
lar events, and (c) all-cause mortality.
Methods
The Salford prospective diabetes cohort provides a 
unique opportunity to determine how the relationship 
between androgen profile, and the cardiometabolic out-
come is modulated by the number of CAG repeats of 
the AR. The cohort of mostly Caucasian individuals with 
T2DM was established in 2002. Follow-up data were 
available on 423 men. Individuals were recruited consec-
utively from outpatient clinics and general practitioner 
(GP) surgeries. We have serum samples and extracted 
DNA for 423 men collected between 2002 and 2004 
with detailed cardiometabolic phenotypic follow-up data 
including mortality data on all these men up to the end 
of 2016. Furthermore, we have details as to all medication 
changes including initiation of testosterone therapy with 
subsequent testosterone levels in which this was done as 
part of routine care.
Participants donated a blood sample for DNA extrac-
tion and circulating hormone/biomarker measurement. 
Blood samples were collected only once (at baseline)/
initial screening and individuals were asked to attend 
fasted (no food and only water from 2300 on the day 
before. In relation to androgen status, only a baseline 
blood test was taken. The project described here is part 
of a larger long-term naturalistic T2DM cohort study 
which aims to provide genetic and epigenetic data to 
inform our understanding of the outcomes for T2DM 
patients in a longer-term follow-up model. We have 
explicit written consent from the participants to obtain 
follow-up health outcome data for them. Ethical permis-
sion was obtained.
We have recently obtained (with full ethics permission) 
the complete cardiometabolic data set for men from 2002 
up to the end of 2016 including mortality data. This data 
set includes changes in weight, BMI, blood pressure, 
and HbA1c/renal indices/lipid profile, plus cardiovascu-
lar complications/neoplasia from GP and hospital-coded 
diagnoses and death. Cardiovascular events were defined 
as stroke, myocardial infarction (MI), angina, and coro-
nary revascularization. Fifty two men did not have avail-
able follow-up data as they had left Salford, with the 
consequence that their health records were no longer 
accessible. CAG analysis was not performed on samples 
from these men.
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We determined baseline androgen status by measuring 
serum testosterone, using tandem mass spectrometry 
at the University Hospital of South Manchester. Also, 
in collaboration with the department of Oncology and 
Metabolism at the University of Sheffield, the num-
ber of CAG repeats for the testosterone receptor gene 
was determined using whole blood-derived DNA. The 
related methodology is summarized below.
Assays
Hormone assays
Baseline androgen profile was determined by measuring 
serum total testosterone using tandem mass spectrom-
etry at University Hospital of South Manchester [17], 
and SHBG, luteinizing hormone (LH), and follicle-stim-
ulating hormone (FSH) by immunoassay at the same 
laboratory.
Free testosterone was estimated using the calculator 
available at http://www.issam.ch/freetesto.htm which is 
based on the Vermeulen Equation [18]. HbA1c and lipid 
profile were determined at Salford Royal Hospital on the 
Menarini 9210 Premier automated analyser (boranate 
affinity and high performance liquid chromatography), 
(Menarini, Wokingham Berkshire, UK).
Determination of the CAG repeat number (423 
individuals)
DNA that had already been extracted from whole blood 
was subjected to PCR for 423 individuals to amplify 
the region of the AR gene containing AR CAG. PCR 
preparation, primers, and conditions were undertaken as 
described in a previous study [6].
Statistical analysis
The CAG distribution was plotted using Kernel density 
estimation. Kernel density estimation is a fundamental 
data smoothing solution where inferences about the pop-
ulation are made, based on a finite data sample.
To explore whether baseline data and characteristics 
were the same across different groups of CAG repeats, 
one-way ANOVA was applied. The number of CAG 
repeats was included as a categorical predictor variable. 
Testosterone at baseline was included as either contin-
uous predictors or as dichotomous variables [normal 
(>12  nmol/L)/borderline (8–12  nmol/L)/low (<8  nmo-
l/L)]. Initially, single predictors were fitted to determine 
whether the continuous or dichotomous variables were 
better at predicting HbA1c. Then a single measure for 
testosterone/free testosterone was included to determine 
the best possible prediction of mean HbA1c/BMI levels 
over time, including BMI and HbA1C at last follow-up. 
Interactions between the predictors and time were then 
added to determine whether there was an effect on the 
rate of change of HbA1c over time. Finally, the number 
of CAG repeats was added to the model to determine 
whether the effect of androgen status is modulated by 
CAG repeat number.
A similar modeling procedure was followed to determine 
the combined effects of CAG repeats and testoster-
one level on mortality and on the risk of cardiovascular 
events. Logistic regression, including age as a covariate, 
was used to determine the influence of CAG repeat num-
ber on mortality as the outcome variable.
Results
Mean (09:00 a.m. to 11:00 a.m.) total testosterone was 
13.7 ± 5.8 nmol/L. A total of 154 (28.0%) of men had 
a low total testosterone (defined as total testosterone 
<10  nmol/L). We chose 10 nmol/L as the mid-point of 
the laboratory reference range for borderline biochemical 
hypogonadism (8–12 nmol/L) [19]. Sixty four men were 
prescribed testosterone replacement either for a short 
period or long term over the follow-up period. Analysis 
of the outcomes for these individuals is the subject of a 
separate study.
The mean age of the men was 59.8 ± 12.5 years. In total, 
175/423 men died during follow-up. The all-cause mor-
tality rate was higher in patients with lower total testos-
terone compared to normal baseline total testosterone 
(5.2% vs 2.9% per year, P < 0.0001) and also for lower 
free testosterone. Over the whole follow-up period, 
36.3% men with normal baseline total testosterone at 
baseline died vs 55.9% of those who were hypogonadal 
at baseline.
Mean baseline BMI (2002) was 29.90 (95% confidence 
interval (CI) 29.45–30.45) with a decrease in mean BMI 
in those still available for follow-up to 29.40 (95% CI 
28.60–30.20). Mean baseline HbA1c (2002) was 8.00% 
(95% CI 7.85–8.17%) (63.9  mmol/mol) increasing to 
a mean HbA1c (2016) of 8.23% (95% CI 8.05–8.40) 
(66.4 mmol/mol) at the last follow-up.
Baseline data by categories of CAG repeats are given in 
Table 1. The highest (n > 23) vs lowest quartile of CAG 
repeats (n < 20) associated with a 1.1 nmol/L higher base-
line testosterone level (F = 1.94, P = 0.02).
Metabolic outcomes
Lower total testosterone was associated with higher BMI 
(kg/m2) at 14-year-follow-up: regression coefficient –0.30 
(95% CI –0.445 to –0.157), P = 0.0001.
For the 423 individuals undergoing CAG repeat analysis, 
the distribution of CAG repeats is shown in Fig. 1. The 
range of CAG repeat number was from 9 to 29 repeats.
A higher CAG repeat number in exon 1 of the AR gene was 
associated with higher follow-up BMI 2016 after a mean 
14-year-follow-up in 2016 such that each unit increase in 
CAG repeat associated with an increment of 0.43 in BMI 
2016 (P = 0.018) (Fig.  2); and also higher HbA1c 2016 
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(Fig. 3) – each unit increase in CAG repeat associated with 
an increment of 0.1% in HbA1C 2016 (P = 0.04). These 
relations were independent of baseline testosterone.
Cardiovascular outcomes and mortality
There was no relation between CAG length and the rate 
of occurrence of MI, coronary artery revascularization, 
angina, or stroke.
At an average 14-year-follow-up, 55.8% of hypogonadal 
men had died vs 36.1% of eugonadal men (P = 0.001). 
In total, 175/423 (41.4%) men died. There was a ‘u’ 
shaped relation between the number of CAG repeats 
and mortality such that 21 CAG repeats was associated a 
lower mortality rate than <21 CAG repeats and >21 CAG 
repeats (Fig.  4). Adjusted logistic regression (including 
adjustment for age) indicated that the presence of 21 
CAG repeats reduced the risk of death by 45% com-
pared with <21 CAG repeats (odds ratio 0.55 (95% CI 
0.28–0.92), P = 0.02; and that >21 repeats increased the 
risk of death by 48% (odds ratio 1.48 (95% CI 1.08–2.37, 
P = 0.015).
Thus, we found an optimal number of CAG repeats in 
relation to mortality rate. This relation was independent 
of baseline testosterone level.
Table 1 Baseline variables (2002) for the Salford diabetes cohort men by number of CAG repeats
CAG repeat number CAG repeat number CAG repeat number CAG repeat number
F, p for difference
≤20 21 22–23 ≥24
N = 150 N = 66 N = 86 N = 121
Age (years) 60.8 (58.1–63.5) 58.8 (55.2–62.3) 56.7(53.2–60.2) 58.8 (56.0–61.5) F 1.25, pNS
BMI (kg/m2) 30.4 (29.2–31.6) 28.0 (26.8–29.3) 28.6 (27.2–30.0) 30.4 (29.1–31.7) F 3.32 P = 0.02
Systolic BP (mmHg) 138 (134–142) 134 (128–140) 134 (129–139) 137 (1340141) F 0.85, pNS
Diastolic BP (mmHg) 77 (74–79) 76 (72–80) 74 (71–77) 77 (75–80) F 0.82 pNS
Hba1c (%) 8.45 (7.98–8.92) 8.43 (7.78–9.10) 8.22 (7.80–8.64) 8.21 (7.84–8.59) F 0.30 pNS
HbA1C (mmol/mol) 68.9 (63.7–74.0) 68.6 (61.5–76.0) 66.3 (61.7–70.9) 66.2 (62.2–70.4) F 0.30 pNS
Total cholesterol (mmol/L) 4.80 (4.53–5.07) 4.65 (4.26–5.04) 4.78 (4.46–5.10) 4.70 (4.47–4.93) F 0.23 pNS
HDL cholesterol (mmol/L) 1.17 (1.10–1.24) 1.25 (1.09–1.40) 1.30 (1.12–1.48) 1.22 (1.12–1.33) F 0.92 pNS
Creatinine (μmol/L) 100.8 (93.2-108.3) 99.9 (93.3–106.5) 94.8 (88.6–101.1) 96.0 (90.7–101.3) F 0.73 p NS
Testosterone (nmol/L) * 13.6 (12.4–14.8) 14.6 (13.1–16.0) 14.2 (12.6–15.8) 14.9 (13.5–16.3) F 1.94 p 0.02
SHBG (nmol/L) * 41.1 (37.5–44.8) 47.1 (41.3–52.9) 41.5 (36.9–46.0) 41.2 (36.7–45.8) F 1.34 pNS
Free testosterone (pmol/L) * 245 (225–266) 244 (222–266) 250 (229–271) 271 (250–293) F 1.41 pNS
Numbers of men shown in brackets for each CAG category. All data are arithmetic means [95% confidence interval (CI)] unless otherwise stated.
Geometric means are denoted by *
Fig. 1
Frequency distribution of CAG repeat number.
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Discussion
We have determined a ‘u’ shaped relation between CAG 
repeat number and mortality rate in this prospective 
cohort study. This has not been described previously 
in such a long-term follow-up study and points to an 
optimum number of CAG repeats in terms of how the 
CAG repeat number influences AR function and respon-
siveness to testosterone, both with a lower and higher 
Fig. 2
Relation between CAG repeat number and BMI 2016. Each unit increase in CAG repeat associated with an increment of 0.43 in BMI 2016 (P = 
0.018).
Fig. 3
Relation between CAG repeat number and HbA1c 2016. Each unit increase in CAG repeat associated with an increment of 0.1% in HbA1C 
2016 (P = 0.04).
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number of CAG repeats than 21 potentially associated 
with greater AR resistance to testosterone.
We also found that a higher number of CAG repeats at 
the testosterone receptor gene is associated with a higher 
future BMI and HbA1c. This is the longest duration 
study in T2DM men to have shown this and indicates 
that CAG repeat number should potentially be taken into 
account in interpreting total testosterone level in relation 
to modulation of longer-term health outcomes in men.
Reasons for the ‘u’ shaped relation between CAG repeat 
number and mortality rate may include influences of a 
low or high CAG repeat number on long-term changes 
(increase) in HbA1c, BMI, and HDL cholesterol or on 
other determinants of cardiovascular outcome.
It is also relevant to note that there was a relation 
between CAG repeat number and total testosterone at 
baseline with the highest (n > 23) vs lowest quartile of 
CAG repeats (n < 20) associated with a 1.1 nmol/L higher 
baseline testosterone level, potentially as a compensation 
for the degree of testosterone resistance conferred by the 
increased number of CAG repeats.
Ethnic variation in disease prevalence can inform our 
understanding of the factors that drive these differ-
ences. Differences in the CAG repeat length of the AR 
gene exist between African, Caucasian, and Asian pop-
ulations [20]. The CAG allele expansion in African men 
was reported at between 18 and 20 [21]. In contrast, 
Caucasian and Asian populations have been shown to 
have a longer CAG expansion, where the mean number 
of CAG repeats is, respectively, 21–22 in Caucasians [22] 
and 23 in Asians [16].
A body of evidence exists indicating that hypogonadism 
is associated with a more adverse metabolic profile and 
cardiovascular risk [9,23]. A lower circulating testoster-
one level in illness caused by cytokine suppression of 
the hypothalamic-pituitary-testicular axis may reflect a 
biological protective effect on the species and not the 
individual. Evidence does support a beneficial action 
of testosterone on atherosclerosis and its clinical con-
sequences [24], however, this has been disputed in the 
literature [25]. Nevertheless, this is the longest duration 
prospective study to describe the potential impact of 
CAG repeats length of the AR on cardiovascular risk and 
lipid profile. The mortality rate in this study is similar to 
that described in the prospective BLAST study [8] and by 
Muraleedharan et al. in the untreated arm of their study 
of testosterone therapy in hypogonadal T2DM men [7].
A previous study on 1859 men aged 20–79 years showed no 
direct correlation between CAG repeat length in the AR 
coding region and cardiometabolic risk factors [26]. Other 
authors also found a neutral effect of the length of AR 
gene polyglutamine tract on lipid levels [27,28]. However, 
in T2DM longer CAG repeat number was associated with 
HDL cholesterol levels but not with total or LDL cho-
lesterol levels [13]. Nevertheless, a shorter CAG repeat of 
Fig. 4
Relation between GAC repeat number and mortality rate. Adjusted logistic regression indicated that the presence of 21 CAG repeats reduced the 
risk of death by 45% compared with <21 CAG repeats [odds ratio 0.55 (95% CI 0.28–0.92), P = 0.02]; and that >21 repeats increased the risk 
of death by 48% [odds ratio 1.48 (95% CI 1.08–2.37, P = 0.015]. CI, confidence interval.
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the AR gene was found by Alevizaki et al. to be associated 
with more severe coronary artery disease (CAD) [27].
Important functions of testosterone in modulating adi-
posity, insulin resistance, and T2DM have been postu-
lated [3,13]. It has been known for some time that total 
testosterone and SHBG levels are lower in men with 
T2DM compared with healthy controls [29] and lower 
than in men with T1DM [30]. In some men, the lower 
SHBG resulted in estimated free testosterone not itself 
being lower in the T2DM men. A longer AR CAG repeat 
was associated with increased body fat and leptin levels 
in a study of 106 healthy men [31] and in a study of 233 
men with T2DM [6]. The latter study demonstrated that 
increased central adiposity as measured by waist circum-
ference was associated with a less sensitive AR. Longer 
AR CAG sequences have also been associated with 
higher serum insulin levels in healthy men [21] and with 
obesity and leptin levels, although they were not shown 
to correlate with HbA1c levels in our study.
There were insufficient individuals in this study to look 
at the relation between testosterone therapy and cardio-
vascular events/CAG repeat number in a way that would 
provide a definitive answer to the question. This is some-
thing that we plan to do once we have a larger cohort as 
the next step in our work.
Strengths and limitations
A strength of the study is the duration of follow-up. A 
limitation of the study is that CAG analysis was not car-
ried out on all the original participants. However, only 52 
men did not have follow-up data. CAG analysis was not 
performed on samples from these men. A further limi-
tation is that the follow-up data was obtained from GP 
records and therefore is limited to what data was rou-
tinely recorded. Also, there were not sufficient follow-up 
testosterone levels to look prospectively at trends in tes-
tosterone over time. Finally, the Salford area population 
is predominantly of Caucasian ethnicity, so we cannot 
draw conclusions concerning other ethnic groups from 
this study in relation to AR status.
Conclusion
In the near future, determination of AR CAG polymor-
phisms may become of clinical relevance because of the 
theoretical possibility of identifying subjects more or less 
at risk for various disorders and more or less responsive 
to testosterone therapy. Furthermore, the study of CAG 
repeat length could allow us to individualise testosterone 
therapy, according to the number of CAG repeats.
A greater understanding of the interaction between CAG 
repeat number and circulating testosterone level adds 
further to our understanding of the endocrine factors 
that determine longer term health outcomes in men with 
T2DM.
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